Q: Now things start to get really interesting.
Still risk with (i) final clinical trial data in early 2019 and FDA approval contingent on that data; and (ii) commercialization risk assuming FDA approval.
Still risk with (i) final clinical trial data in early 2019 and FDA approval contingent on that data; and (ii) commercialization risk assuming FDA approval.